drugset / Trial / NCT00503750
Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase II one arm study. Patients with HER2 (Human Epidermal Growth Factor Receptor 2)positive early stage breast cancer will receive ABI-007 and vinorelbine in combination with trastuzumab before having breast surgery.
Timeline
- Start
- 2008-04
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Paclitaxel | Small molecule | 260 mg/m2 | Other |
| Comparator | Trastuzumab | Monoclonal antibody | 2 mg/kg | Other |
| Comparator | Vinorelbine | Small molecule | 25 mg/m2 | Other |